Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Relay Therapeutics, Inc. (RLAY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue: License and other revenue $ 119 $ 365 $ 345 $ 784 Total revenue 119 365 345 784 Operating expenses: Research and development expenses $ 88,201 $ 60,511 $ 171,028 $ 112,178 Change in fair value of contingent consideration liability 200 General and administrative expenses 20,120 17,465 39,699 33,533 Total operating expenses 106,169 78,176 207,572 141,316 Loss from operations Other income: Interest income 7,559 1,005 14,500 1,701 Other income 18 Total other income, net 7,545 1,023 14,483 1,698 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average shares of common stock, basic and diluted 121,680,844 108,644,329 121,501,849 108,469,760 Other comprehensive loss: Unrealized holding ga...",
"X FGFR1 FGFR2 FGFR3 FGFR4" |
|
| 08/04/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 03/25/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results |
| 08/27/2020 |
8-K
| Quarterly results |
|
|